These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27196765)

  • 1. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 3. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ; Casalvieri KA; Backos DS; Reigan P
    ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
    Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
    ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
    Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.